About 8 in 10 infants received respiratory syncytial virus protection during the 2023 to 2024 season, according to study findings.

Doxycycline postexposure prophylaxis initiation is associated with decreases in sexually transmitted infections.

Coffee drinking timing is associated with all-cause and cardiovascular disease-specific mortality risk, according to study findings.

One in four older US veterans report being diagnosed with cardiovascular disease in their lifetime, according to study findings.

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

For immunocompromised individuals, antibody response to RSV vaccines is heterogeneous and about 40% do not seroconvert.

Adoption of the Acute Hospital Care at Home program is mainly limited to specific types of hospitals, according to study findings.

Telemedicine is not reliable for assessing Centor criteria for patients with an acute sore throat, according to study findings.

The first-ever US FDA guidelines on lead in baby food are under fire from health experts who argue the limits are too lenient and fail to protect children from harmful exposure to toxic metals.

The all-cause hospitalization rate at 28 days is high among adults with outpatient medically attended RSV infections.